본문 바로가기 주메뉴 바로가기
22대 대한민국 국회 국회정보길라잡이 국회의원검색
회원가입 로그인
HOME

정보검색

소장정보 검색

국회도서관 홈으로 정보검색 소장정보 검색
결과 내 검색 동의어 포함
결과 내 검색 동의어 포함

-

초록보기

Purpose There have been needs to improve the sensitivity of liquid biopsy. This report aims to report the analytical and clinical validation of a next-generation sequencing (NGS)–based circulating tumor DNA (ctDNA) assay.

Materials and Methods Analytical validation was conducted in vitro by evaluating the limit of detection (LOD), precision, and specificity for various genomic aberrations. The real-world performance in non–small cell lung cancer (NSCLC) was assessed by comparing the results of AlphaLiquid100 to the tissue-based results.

Results The LODs with 30 ng input DNA were 0.11%, 0.11%, 0.06%, 0.21%, and 2.13 copies for detecting single nucleotide variants, insertions, deletions, fusions, and copy number alterations (CNA), respectively. Quantitatively, single nucleotide variants/insertions and deletions, fusions, and CNAs showed a good correlation (R2=0.91, 0.40, and 0.65; y=0.95, 1.06, and 1.19) to the manufacturer’s values, and per-base specificities for all types of variants were near 100%. In real-world NSCLC (n=122), key actionable mutations in NSCLC were detected in 60.7% (74/122) with the ctDNA assay. Comparative analysis against the NGS-based tissue results for all key mutations showed positive percent agreement (PPA) of 85.3%. For individual genes, the PPA was as high as 95.7% for epidermal growth factor receptor (EGFR) mutations and 83.3% for ALK translocations. AlphaLiquid100 detected drug-sensitive EGFR mutation at a variant allele frequency as low as 0.02% and also identified an EGFR mutation in a case where tissue sample missed. Blood samples collected post-targeted therapies revealed additional acquired mutations.

Conclusion The AlphaLiquid100 ctDNA assay demonstrates robust analytical validity, offering clinically important information for NSCLC patients.

권호기사

권호기사 목록 테이블로 기사명, 저자명, 페이지, 원문, 기사목차 순으로 되어있습니다.
기사명 저자명 페이지 원문 목차
HER2-low breast cancer : now and in the future Sora Kang, Sung-Bae Kim p. 700-720

Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer : a joint report from KSMO and KSP Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo ... [et al.] p. 721-742

Phase 1/2a study of rivoceranib, a selective VEGFR-2 angiogenesis inhibitor, in patients with advanced solid tumors Yoon-Koo Kang, Min-Hee Ryu, Yong Sang Hong, Chang-Min Choi, Tae Won Kim, Baek-Yeol Ryoo, Jeong Eun Kim, John R. Weis, Rachel Kingsford, Cheol Hee Park, Seong Jang, Arlo McGinn, Theresa L. Werner, Sunil Sharma p. 743-750

Association of immune-related adverse events and the efficacy of anti-PD-(L)1 monotherapy in non-small cell lung cancer : adjusting for immortal-time bias Ying Yu, Ning Chen, Sizhe Yu, Wanji Shen, Wanchen Zhai, Hui Li, Yun Fan p. 751-764

Analytical and clinical validation of a highly sensitive NGS-based ctDNA assay with real-world concordance in non-small cell lung cancer Hanbaek Yi, Jeonghwan Youk, Yoojoo Lim, Hanseong Roh, Dongsoo Kyung, Hwang-Phill Kim, Duhee Bang, Bhumsuk Keam, Tae-Min Kim, Miso Kim, Dong-Wan Kim, Tae-You Kim p. 765-773

Comparison of clinicopathogenomic features and treatment outcomes of EGFR and HER2 Exon 20 insertion mutations in non-small cell lung cancer : single-institution experience So Heun Lee, Hyehyun Jeong, Deok Hoon Kim, Se Jin Jang, Sang-We Kim, Shinkyo Yoon, Dae Ho Lee p. 774-784

Contribution of enhanced locoregional control to improved overall survival with consolidative durvalumab after concurrent chemoradiotherapy in locally advanced non-small cell lung cancer : insights from real-world data Jeong Yun Jang, Si Yeol Song, Young Seob Shin, Ha Un Kim, Eun Kyung Choi, Sang-We Kim, Jae Cheol Lee, Dae Ho Lee, Chang-Min Choi, Shinkyo Yoon, Su Ssan Kim p. 785-794

Trastuzumab Biosimilar (HLX02), pertuzumab plus chemotherapy in patients with HER2-positive metastatic breast cancer after progression of trastuzumab : a prospective, phase Ⅱ study Ruyan Zhang, Xiaoran Liu, Guohong Song, Yan Zhang, Huiping Li p. 795-801

Implementation of BRCA test among young breast cancer patients in South Korea : a nationwide cohort study Yung-Huyn Hwang, Tae-Kyung Yoo, Sae Byul Lee, Jisun Kim, Beom Seok Ko, Hee Jeong Kim, Jong Won Lee, Byung Ho Son, Il Yong Chung p. 802-808

(The) clinical efficacy of colorectal cancer patients with pulmonary oligometastases by sterotactic body ablative radiotherapy : a meta-analysis Jae-Uk Jeong, Chai Hong Rim, Gyu Sang Yoo, Won Kyung Cho, Eui Kyu Chie, Yong Chan Ahn, Jong Hoon Lee p. 809-824

(The) persistence of hypertriglyceridemia and the risk of early onset colorectal cancer according to tumor subsites : a nationwide population-based study Young Hoon Chang, Cheol Min Shin, Kyungdo Han, Jin Hyung Jung, Eun Hyo Jin, Joo Hyun Lim, Seung Joo Kang, Yoon Jin Choi, Hyuk Yoon, Young Soo Park, Nayoung Kim, Dong Ho Lee p. 825-837

Combined high-dose radiotherapy with sequential gemcitabine-cisplatin based chemotherapy increase the resectability and survival in locally advanced unresectable intrahepatic cholangiocarcinoma : a multi-institutional cohort study Jung Ho Im, Jeong Il Yu, Tae Hyun Kim, Tae Gyu Kim, Jun Won Kim, Jinsil Seong p. 838-846

Global expanded access program for pemigatinib in patients with previously treated locally advanced or metastatic cholangiocarcinoma and fibroblast growth factor receptor gene alterations Anouk Lindley, Gerald Prager, Michael Bitzer, Timothy C. Burn, Christine F. Lihou, Elisabeth Croft p. 847-855

Invasiveness of upper tract urothelial carcinoma : clinical significance and integrative diagnostic strategy Bokyung Ahn, Doeun Kim, Kye Jin Park, Ja-Min Park, Sun Young Yoon, Bumsik Hong, Yong Mee Cho, Deokhoon Kim p. 856-870

Adjuvant chemotherapy for upper tract urothelial carcinoma : a real-world, retrospective study Junho Lee, Sung Hee Lim, Jae Hoon Chung, Wan Song, Hyun Hwan Sung, Byong Chang Jeong, Se Hoon Park p. 871-876

Single early intravesical instillation of epirubicin for preventing bladder recurrence after nephroureterectomy in upper urinary tract urothelial carcinoma Jong Hoon Lee, Chung Un Lee, Jae Hoon Chung, Wan Song, Minyong Kang, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Hwan Sung p. 877-884

Bilateral seminal vesicle invasion as a strong prognostic indicator in T3b prostate cancer patients following radical prostatectomy : a comprehensive, multicenter, long-term follow-up study Jungyo Suh, In Gab Jeong, Hwang Gyun Jeon, Chang Wook Jeong, Sangchul Lee, Seong Soo Jeon, Seok-Soo Byun, Cheol Kwak, Hanjong Ahn p. 885-892

Neoadjuvant cisplatin-based chemotherapy followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of the bladder : post hoc analysis of two prospective studies Sung Wook Cho, Sung Hee Lim, Ghee Young Kwon, Chan Kyo Kim, Won Park, Hongryull Pyo, Jae Hoon Chung, Wan Song, Hyun Hwan Sung, Byong Chang Jeong, Se Hoon Park p. 893-897

Predicted cervical cancer prevention : impact of national HPV vaccination program on young women in South Korea Kyeongmin Kwak, Seung-sik Hwang p. 898-908

(The) role of early and delayed surgery for infants with congenital brain tumors Jong Seok Lee, Ji Yeoun Lee, Kyung Hyun Kim, Sung-Hye Park, Eun Jung Koh, Seung-Ki Kim, Ji Hoon Phi p. 909-919

Feasibility of circulating tumor DNA analysis in patients with follicular lymphoma Sang Eun Yoon, Seung-Ho Shin, Dae Keun Nam, Junhun Cho, Won Seog Kim, Seok Jin Kim p. 920-935

Secondary malignancies in multiple myeloma in Korean patients : a nationwide population-based study Boyoung Park, Eunyoung Lee, Junghyun Yoon, YoungJu Park, Hyeon-Seok Eom p. 936-944

CD19-specific CAR-T cell treatment of 115 children and young adults with acute B lymphoblastic leukemia : long-term follow-up Yu Wang, Yu-juan Xue, Ying-xi Zuo, Yue-ping Jia, Ai-dong Lu, Hui-min Zeng, Le-ping Zhang p. 945-955

Nation-wide retrospective analysis of allogeneic stem cell transplantation in patients with multiple myeloma : a study from Korean Multiple Myeloma Working Party (KMM1913) Ho-Jin Shin, Do-Young Kim, Kihyun Kim, Chang-Ki Min, Je-Jung Lee, Yeung-Chul Mun, Won-Sik Lee, Sung-Nam Lim, Jin Seok Kim, Joon Ho Moon, Da Jung Kim, Soo-Mee Bang, Jong-Ho Won, Jae-Cheol Jo, Young Il Koh p. 956-966

Molecular and treatment characteristics of SMARCB1 or SMARCA4-deficient undifferentiated tumor : retrospective case series Hyeon Gyu Kang, Jiwon Koh, Tae Min Kim, Doo Hee Han, Tae-Bin Won, Dong-Wan Kim, Dong-Young Kim, Bhumsuk Keam p. 967-971

(Correspondence) Bridging the gap between trial adverse events and real-world data Sang Hyuk Kim, Hyun Lee, Dong Won Park p. 972-973

참고문헌 (20건) : 자료제공( 네이버학술정보 )

참고문헌 목록에 대한 테이블로 번호, 참고문헌, 국회도서관 소장유무로 구성되어 있습니다.
번호 참고문헌 국회도서관 소장유무
1 Bioinformatics. 2009 Jul 15;25(14):1754-60 미소장
2 Mol Cancer. 2022 Mar 18;21(1):79 미소장
3 PLoS One. 2020 Sep 25;15(9):e0237802 미소장
4 J Thorac Oncol. 2021 Oct;16(10):1647-1662 미소장
5 Cell Mol Biol (Noisy-le-grand). 2023 Aug 31;69(8):89-95 미소장
6 Ann Oncol. 2023 Apr;34(4):339-357 미소장
7 ESMO Open. 2021 Apr;6(2):100060 미소장
8 Curr Oncol. 2023 Jan 01;30(1):575-585 미소장
9 PLoS One. 2020 May 7;15(5):e0232754 미소장
10 Clin Cancer Res. 2015 Jul 15;21(14):3196-203 미소장
11 JTO Clin Res Rep. 2022 Mar 08;3(4):100301 미소장
12 Cancer Discov. 2021 Apr;11(4):858-873 미소장
13 Nat Med. 2022 Nov;28(11):2353-2363 미소장
14 Cancers (Basel). 2023 May 20;15(10): 미소장
15 J Thorac Oncol. 2018 Sep;13(9):1248-1268 미소장
16 Clin Cancer Res. 2023 Apr 14;29(8):1506-1514 미소장
17 Genes Genomics. 2020 Jul;42(7):751-759 미소장
18 Nat Med. 2020 Dec;26(12):1859-1864 미소장
19 Nat Rev Cancer. 2017 Apr;17(4):223-238 미소장
20 Clin Cancer Res. 2015 May 15;21(10):2379-87 미소장

추천서가 (다양한 추천 자료를 만나보세요)

권호기사보기

권호기사 목록 테이블로 기사명, 저자명, 페이지, 원문, 기사목차 순으로 되어있습니다.
기사명 저자명 페이지 원문 기사목차